Literature DB >> 10815624

Quantitative clinical radiobiology of early and late lung reactions.

S M Bentzen1, J Z Skoczylas, J Bernier.   

Abstract

PURPOSE: To quantify the response of human lung to a course of fractionated radiotherapy based on a literature review of published clinical data.
MATERIALS AND METHODS: Quantitative clinical radiobiology is concerned with the estimation of parameters that describe the clinical outcome of radiotherapy as a function of patient and treatment characteristics. Here, parameters describing the steepness of the dose-response curve, the response to a change in dose per fraction and to a change in overall treatment time for early and late lung injury are compiled based on published clinical studies.
RESULTS: Two phases of lung injury are seen, radiation pneumonitis and lung fibrosis. The first signs of early lung changes are seen almost immediately after irradiation. This reaction peaks after 5 to 6 months, and settles partially before 9-10 months. Around that time, the late changes become manifest and these are stable in most cases. There is an important distinction between lung injury and radiotherapy-related morbidity, as even severe changes in a small volume may not give rise to any clinical symptoms. Many assays have been developed for lung damage, and these highlight various clinical and biological aspects of lung damage. Here, the literature on steepness of dose-response curves and fractionation sensitivity is reviewed and quantified by the alpha/beta ratio of the linear-quadratic model for both radiation pneumonitis and lung fibrosis. For the early phase a significant time factor exists. Current best estimates for these radiobiological parameters are derived. Other external factors affecting these estimates are briefly discussed.
CONCLUSIONS: Quantitative estimates of radiobiological characteristics of human lung are available for the pneumonitis phase where the fractionation sensitivity is in the same range as for most late-responding normal tissues. Short intensive schedules may also bear an added risk for pneumonitis as the dose recovered per day is around 0.5 Gy. For the later phase of lung fibrosis, the estimates are fewer and generally less precise. It is clear though, that the alpha/beta ratio is low, possibly 2-3 Gy. No time factor has been demonstrated for the late reaction. Due to the considerable physiological reserve capacity in the normal human lung, the relationship between damage and morbidity depends strongly on the lung volume affected. It therefore seems likely that for small volumes irradiated to high doses, the dose-limiting complications may not be due to restriction of lung function, but rather to haemorrhage and formation of fistulae.

Entities:  

Mesh:

Year:  2000        PMID: 10815624     DOI: 10.1080/095530000138448

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  16 in total

Review 1.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Correlation between pneumonitis risk in radiation oncology and lung density measured with X-ray computed tomography.

Authors:  Abdulhamid Chaikh; Jacques Balosso
Journal:  Quant Imaging Med Surg       Date:  2016-08

3.  Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouse.

Authors:  Mitchell Machtay; Arnaud Scherpereel; José Santiago; James Lee; Jim McDonough; Paul Kinniry; Evguenia Arguiri; Vladimir V Shuvaev; Jing Sun; Keith Cengel; Charalambos C Solomides; Melpo Christofidou-Solomidou
Journal:  Radiother Oncol       Date:  2006-10-27       Impact factor: 6.280

4.  Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients.

Authors:  Christos Nanos; Vasilios Souftas; Athanasios Zissimopoulos; Michael I Koukourakis
Journal:  Radiat Oncol J       Date:  2022-06-20

5.  Experimental stereotactic irradiation of normal rabbit lung: computed tomographic analysis of radiation injury and the histopathological features.

Authors:  Takatsugu Kawase; Etsuo Kunieda; Hossain M Deloar; Satoshi Seki; Akitomo Sugawara; Takanori Tsunoo; Eileen N Ogawa; Akitoshi Ishizaka; Kaori Kameyama; Atsuya Takeda; Atsushi Kubo
Journal:  Radiat Med       Date:  2007-11-26

6.  Radon and COPD mortality in the American Cancer Society Cohort.

Authors:  Michelle C Turner; Daniel Krewski; Yue Chen; C Arden Pope; Susan M Gapstur; Michael J Thun
Journal:  Eur Respir J       Date:  2011-10-17       Impact factor: 16.671

7.  A model of photon cell killing based on the spatio-temporal clustering of DNA damage in higher order chromatin structures.

Authors:  Lisa Herr; Thomas Friedrich; Marco Durante; Michael Scholz
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

8.  Complication probability models for radiation-induced heart valvular dysfunction: do heart-lung interactions play a role?

Authors:  Laura Cella; Giuseppe Palma; Joseph O Deasy; Jung Hun Oh; Raffaele Liuzzi; Vittoria D'Avino; Manuel Conson; Novella Pugliese; Marco Picardi; Marco Salvatore; Roberto Pacelli
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

9.  Protein Oxidation in the Lungs of C57BL/6J Mice Following X-Irradiation.

Authors:  Michal Barshishat-Kupper; Elizabeth A McCart; James G Freedy; Ashlee J Tipton; Vitaly Nagy; Sung-Yop Kim; Michael R Landauer; Gregory P Mueller; Regina M Day
Journal:  Proteomes       Date:  2015-08-19

10.  Palliative radiotherapy in locally advanced head and neck cancer after failure of induction chemotherapy: comparison of two fractionation schemes.

Authors:  Kailash Chandra Pandey; Swaroop Revannasiddaiah; Nirdosh Kumar Pant; Vipul Nautiyal; Madhup Rastogi; Manoj Kumar Gupta
Journal:  Indian J Palliat Care       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.